10x Genomics, Inc. (NASDAQ:TXG) CEO Serge Saxonov Sells 5,092 Shares of Stock

10x Genomics, Inc. (NASDAQ:TXG) CEO Serge Saxonov sold 5,092 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $56,368.44. Following the sale, the chief executive officer now directly owns 879,482 shares in the company, valued at approximately $9,735,865.74. The trade was a 0.58 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

10x Genomics Price Performance

Shares of 10x Genomics stock opened at $11.65 on Thursday. 10x Genomics, Inc. has a 1 year low of $10.63 and a 1 year high of $48.42. The firm’s 50-day moving average is $14.13 and its two-hundred day moving average is $16.92. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -7.66 and a beta of 1.85.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. On average, equities analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on TXG. Citigroup decreased their price target on shares of 10x Genomics from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Stifel Nicolaus reduced their target price on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Leerink Partners downgraded shares of 10x Genomics from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $25.00 to $12.00 in a research note on Thursday, February 13th. Morgan Stanley reduced their target price on shares of 10x Genomics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Finally, Barclays reduced their target price on shares of 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $20.57.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. grew its position in shares of 10x Genomics by 355.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company’s stock worth $8,027,000 after buying an additional 277,355 shares during the last quarter. Entropy Technologies LP grew its position in shares of 10x Genomics by 285.6% in the 4th quarter. Entropy Technologies LP now owns 37,595 shares of the company’s stock worth $540,000 after buying an additional 27,844 shares during the last quarter. Geode Capital Management LLC boosted its stake in 10x Genomics by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company’s stock worth $41,009,000 after purchasing an additional 42,777 shares in the last quarter. SG Americas Securities LLC boosted its stake in 10x Genomics by 209.8% in the 4th quarter. SG Americas Securities LLC now owns 73,046 shares of the company’s stock worth $1,049,000 after purchasing an additional 49,468 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in 10x Genomics in the 3rd quarter worth approximately $27,778,000. Hedge funds and other institutional investors own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.